Expert Interview
A look at the phase 3 CodeBreak 200 trial of Lumakras' (sotorasib) superior progression-free survival over Docetaxel presented at the ESMO 20222 Conference in NSCLC
Ticker(s): AMGNInstitution: Rocky Mountain Oncology Center
- Oncologist at Rocky Mountain Oncology Center
- Board certified in Medical Oncology and Hematology
- Manages 26 patients with non small cell lung cancer and is very familiar with the phase 3 CodeBreak 200 trial for Lumakras
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
